SCHEDULE 13G: Baker Bros. Advisors Discloses 6.8% Stake in Candel Therapeutics

Baker Bros. Advisors LP and its affiliates have reported a 6.8% beneficial ownership stake in Candel Therapeutics, Inc., holding 2,981,983 shares of common stock as of December 31, 2024.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Candel Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 2,981,983 shares of Candel Therapeutics, Inc. common stock.
• This ownership represents 6.8% of the outstanding common stock of Candel Therapeutics, Inc.
• The beneficial ownership is primarily held through Baker Brothers Life Sciences, L.P., which owns 6.2% (2,728,510 shares), and 667, L.P., which owns 0.6% (253,473 shares).
• The percentage of beneficial ownership is calculated based on 44,125,137 shares of common stock outstanding as of December 16, 2024, as reported in the Issuer's Prospectus.
• The Reporting Persons have sole voting and sole dispositive power over all 2,981,983 shares.
• The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The Reporting Persons also hold pre-funded warrants with no expiration date and an exercise price of $0.01 per share, but these are not currently exercisable due to a 4.99% beneficial ownership limitation (the "Maximum Percentage").
• The Maximum Percentage can be increased to 19.99% by written notice to the Issuer, but any such increase would not be effective until 61 days after the notice is delivered.

Sentiment

Score: 5

Explanation: The filing itself is a neutral, factual regulatory disclosure. However, the disclosure of a significant stake by a reputable life sciences investor like Baker Bros. Advisors can be perceived as a moderately positive signal for the company, suggesting investor confidence.

Positives

• A significant institutional investor, Baker Bros. Advisors, has disclosed a 6.8% stake in Candel Therapeutics, which can be viewed as a vote of confidence in the company.
• The filing indicates a passive investment intent, stating the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Future Outlook

The document is a beneficial ownership filing and does not provide forward-looking statements or guidance regarding Candel Therapeutics, Inc.'s future operations or financial performance.

Industry Context

Schedule 13G filings are routine disclosures by passive investors holding more than 5% of a company's stock. Baker Bros. Advisors is a prominent investment firm specializing in life sciences, and their investment in Candel Therapeutics aligns with their typical focus on biotechnology and pharmaceutical companies. This filing indicates a significant, passive stake by a specialized institutional investor in the biotech sector.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) and does not contain performance metrics or operational results that would allow for a direct comparison to industry standards or specific comparable companies/projects. It solely reports beneficial ownership.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent institutional investor like Baker Bros. Advisors may positively influence investor sentiment and potentially the stock price, signaling confidence in the company.

Next Steps

• The document does not specify any future actions, events, or milestones for Candel Therapeutics or the Reporting Persons beyond the regulatory filing itself. The pre-funded warrants have a mechanism for increasing the maximum percentage of ownership, which would require a 61-day notice to the Issuer.

Key Dates

Keywords

Candel Therapeutics, Baker Bros. Advisors, Schedule 13G, beneficial ownership, common stock, institutional investment